Bcr-abl Tyrosine Kinase Inhibitors [gleevec (imatinib Mesylate), Tasigna (nilotinib), Bosulif (bosutinib), Sprycel (dasatinib), Iclusig (ponatinib Hydrochloride)] - Risk Of Hepatitis B Reactivation

Recall Summary Several tyrosine kinase inhibitor medications used to treat certain blood cancers—Gleevec, Tasigna, Bosulif, Sprycel, and Iclusig—are being recalled across Canada because they can increase the risk of hepatitis B reactivation in patients who carry the hepatitis B virus. Patients taking these medications who have a history of hepatitis B infection or are hepatitis B carriers should contact their healthcare provider. This recall affects all patients in Canada using these drugs.

Reason

Product safety

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2016-05-04

Status

Closed

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/d4e4925a-bceb-4bf1-bcf0-b2ff69543b1f